We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Life Sciences

  • July 26, 2018

    UK Tribunal Won't Pause Epilepsy Drug Case For Appeals

    A U.K. tribunal on Wednesday refused to pause the U.K. competition authority's review of a case accusing Pfizer and Flynn Pharma of charging the National Health Service excessive and unfair prices for an anti-epilepsy drug, ordering the watchdog to take another look as both sides consider appeals.

  • July 26, 2018

    Media Can't Access Drug Co. Data In Opioid MDL

    An Ohio federal judge on Thursday blocked media access to voluminous drug company data divulged in multidistrict litigation over the opioid crisis, concluding that publicity would undermine a delicate discovery process in the high-stakes case.

  • July 26, 2018

    What You Need To Know About Trump's EU Trade Epiphany

    In a span of 10 days, President Donald Trump went from ripping the European Union as a “foe” that has “clobbered” the U.S. on trade to proudly posting a photo of himself receiving a kiss on the cheek from the president of the European Commission following their vow to launch new trade talks. Here, Law360 fills you in on a move with big implications for the transatlantic powerhouses.

  • July 26, 2018

    King & Spalding Nabs IP Partner From Paul Hastings

    King & Spalding LLP said Thursday that it has added an intellectual property partner from Paul Hastings LLP to its trial and global disputes practice, in the most recent of many additions to the firm’s New York office this summer.

  • July 26, 2018

    Shkreli Atty Deserves At Least 5 Years In Prison, Feds Say

    A former Katten Muchin Rosenman attorney convicted by a Brooklyn jury on conspiracy charges last year deserves at least five years in prison for aiding "pharma bro" Martin Shkreli in a scheme to defraud hedge fund investors, the federal government argued Wednesday in a sentencing memorandum.

  • July 25, 2018

    Pharma Statisticians Say Insider Trading Trial Was Tainted

    Two statisticians convicted of swapping confidential stock tips about their pharma employers' test-stage drugs asked a Massachusetts federal court Tuesday to replace their insider trading convictions with judgments of acquittal, saying the evidence shown to the jury diverged from federal prosecutors' charges.

  • July 25, 2018

    House Votes To Extend Exemption From ACA Insurer Fee

    The U.S. House of Representatives voted Wednesday to extend a moratorium on an annual fee on insurers under the Affordable Care Act until 2022.

  • July 25, 2018

    Clint Eastwood Sues Medical Co. For Patent Investments

    Hollywood legend Clint Eastwood claims in a suit filed Tuesday in New York federal court that patents for treatments aimed at fighting diabetes and other diseases, in which he says he invested, were unlawfully ripped away from their inventor by a medical company while the man was recovering from a stroke.

  • July 25, 2018

    Gene Editing Co. Bluebird Bio Offers 3.4M Shares At $162

    Bluebird Bio Inc. put up for sale nearly 3.4 million more shares of common stock this week at $162.50 per share in a public offering from the longtime member of the bio-pharma hub in  Cambridge, Massachusetts. 

  • July 25, 2018

    Discovery War Breaks Out In Opioid MDL Bellwethers

    A simmering discovery dispute in multidistrict litigation over the opioid crisis has boiled over, according to court filings late Tuesday that show drugmakers and pharmacies going public with heated objections over the "unprecedented breadth" and “massive scope" of document disclosures.

  • July 25, 2018

    Novo Nordisk Says Execs Didn't Hide Insulin Sales Woes

    Danish insulin maker Novo Nordisk A/S on Wednesday urged a New Jersey federal judge to dismiss a proposed class action accusing it of misleading investors about its financial sustainability amid U.S. market pressures, arguing that the suing investors haven't pointed to any specific misrepresentations knowingly made by company executives.

  • July 25, 2018

    EU, US Making A Bid To Cool Rising Trade Tensions

    The U.S. and European Union agreed on Wednesday to begin new discussions aimed at slashing tariffs and other trade barriers on both sides of the Atlantic, with a particular focus on industrial goods and energy products as part of an effort to ease tensions between the economic powerhouses.

  • July 25, 2018

    USCIS Policy Changes Put STEM Students On Shaky Footing

    U.S. Citizenship and Immigration Services recently made it more difficult for certain international STEM students to obtain postgraduate temporary work authorization, forcing employers to either prepare to shoulder additional legal burdens on behalf of their foreign hires or look elsewhere to fill specialized roles, attorneys say.

  • July 25, 2018

    Fenwick-Led Bloom Energy Leads 2 IPOs Raising $337.5M

    Advised by Fenwick & West LLP, clean energy power generator Bloom Energy Corp. opened trading in its initial public offering on Wednesday morning, as did the Dechert LLP-led pharmaceutical company Aquestive Therapeutics Inc., with each opening at a $15 share price and combined raising a projected $337.5 million.

  • July 25, 2018

    Boston Scientific Chips Away At Nevro Patents, Beats IP Suit

    A California federal judge invalidated several claims of four Nevro Corp. patents covering spinal cord stimulation technology Tuesday and ruled that Boston Scientific Corp. didn’t infringe the remaining claims with its own technology.

  • July 25, 2018

    Wis. Tribe Reaches Deal With State Over Hemp Program

    The St. Croix Chippewa Indians of Wisconsin and Wisconsin Attorney General Brad Schimel agreed on Wednesday to a deal to end the tribe’s suit seeking to allow it to go forward with a hemp and nonpsychoactive hemp oil program on its land without the danger of criminal prosecution from state authorities.

  • July 25, 2018

    From Billable Hours To Bedtime Stories: Lawyering With Children

    Attorneys are clocking more billable hours than ever before, and when children enter the picture, the demands on their time and finances can drive stress levels to new heights.

  • July 24, 2018

    Minn. Tribe Sues Drugmakers, Distributors Over Opioid Crisis

    A Minnesota American Indian tribe is the latest entity to sue opioid manufacturers and distributors over the public health crisis they allegedly cultivated, telling a federal court Monday that Endo, Purdue, McKesson and numerous others pushed deadly drugs into patients' hands while lying about the attendant likelihood of tragic consequences.

  • July 24, 2018

    Feds Try To Clear Up Ex-Insys Execs’ RICO Charge For Judge

    After a contentious hearing last week, federal prosecutors charging several former Insys Therapeutics Inc. executives with conspiring to bribe doctors so they’d prescribe the company’s fentanyl spray tried to explain the racketeering charges to a puzzled Massachusetts federal judge and promised a new, streamlined indictment in a memorandum filed Tuesday morning.

  • July 24, 2018

    2nd Circ. Nixes Class Cert. In J&J 'Natural' Baby Wash Suit

    The Second Circuit on Tuesday decertified a class of consumers alleging that Johnson & Johnson's Aveeno baby washes were mislabeled as containing “natural” ingredients, finding that a lower court didn’t analyze differences between nearly 20 states’ consumer protection laws.

Expert Analysis

  • A Cloud On The Horizon: Trade Secret Theft In The Cloud

    Amy Van Zant

    Although courts and companies have at times struggled to keep pace with the rapidly evolving challenges surrounding the use of cloud-based software, some best practices have emerged from the body of case law addressing claims of cloud-based appropriation of trade secrets, say attorneys with Orrick Herrington & Sutcliffe LLP.

  • What High Court Review Of Fosamax Means For Preemption

    Max Kennerly

    With the U.S. Supreme Court's grant of certiorari in Fosamax, drug companies may be hoping the court throws out the preemption precedent established by Wyeth v. Levine. But unless multiple justices reverse course and adopt positions contrary to their prior opinions, there simply is no path to victory for drug companies, says Max Kennerly of Kennerly Loutey LLC.

  • Limiting Law Firms' Professional Liability Risks: Part 2

    Stuart Pattison

    With law firms increasingly exposed to professional liability risks associated with their corporate client relationships, firms must craft well-structured client engagement letters to help protect against malpractice claims. Two key elements of an engagement letter are how it defines the scope of engagement and how it handles conflicts of interest, say Stuart Pattison and John Muller of Sompo International Holdings Ltd.

  • Series

    From Lawmaker To Lawyer: Prioritizing Is Always Key

    Joe Lieberman

    Today, members of Congress often seem able to blame colleagues of the other party for not getting anything done for their constituents. In law practice, you can’t really blame a bad result for your clients on the lawyers on the other side, says former Sen. Joe Lieberman, D-Conn., of Kasowitz Benson Torres LLP.

  • Limiting Law Firms' Professional Liability Risks: Part 1

    Stuart Pattison

    Corporate law departments are increasingly demanding more concessions from outside legal counsel, and presenting engagement letters that open the door to greater professional and cyber liability exposure for law firms — often beyond the scope of their insurance coverage. Firms must add their own language to engagement letters to limit liability, say Stuart Pattison and John Muller of Sompo International Holdings Ltd.

  • Series

    From Lawmaker To Lawyer: How Congress Affected My Career

    Yvonne B. Burke

    Being a former member of Congress put me in an advantageous position when I approached law firms in the late '70s, at a time when there were few female lawyers, and even fewer African-American lawyers, in major law firms, says former Rep. Yvonne B. Burke, D-Calif., a director of Amtrak.

  • Series

    From Lawmaker To Lawyer: DC Isn't As Bad As You Think

    Norm Coleman

    Popular culture paints the Hill as a place teeming with intrigue, corruption and malicious intent. But in Congress I learned important lessons about respecting people and the work they do, says former Sen. Norm Coleman, R-Minn., of Hogan Lovells.

  • Supreme Court Decision Weakens Deference To Foreign Laws

    Valarie Williams

    The U.S. Supreme Court's holding in Animal Science v. Hebei that a U.S. court is not bound by a foreign government's interpretation of its own laws is likely to have a lasting impact on legal decision-makers across the globe as they make determinations about deference to foreign laws, including U.S. laws, say attorneys at Alston & Bird LLP.

  • Blockchain Technology Can Help Fight Counterfeit Drugs

    Nancy Urizar

    Blockchain technology can be used to develop a system that would allow trading partners to track and trace drugs across the supply chain, ensuring that counterfeit drugs do not enter the market. However, the pharmaceutical industry will need to evaluate the legal implications of incorporating blockchain into the supply chain, says Nancy Urizar of Womble Bond Dickinson LLP.

  • Series

    From Lawmaker To Lawyer: 6 Things I Learned In Congress

    Charles Gonzalez

    I found that senior members of Congress didn’t have time to mentor younger members. Lawyers — though just as busy as members of Congress — cannot afford to follow this model, says former Rep. Charles Gonzalez, D-Texas, of Ogletree Deakins Nash Smoak & Stewart PC.